2020 2021 PHARMACEUTICAL INDUSTRY RESIDENCY PROGRAM
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
FLORIDA & UNIVERSITY
AND BRISTOL MYERS SQUIBB
PHARMACEUTICAL INDUSTRY
RESIDENCY PROGRAM
2020 - 2021
5"#-&0'$0/5&/54
%FBS 1SPTQFDUJWF 3FTJEFOUT
"CPVU'MPSJEB".6OJWFSTJUZ
"CPVU#SJTUPM .ZFST4RVJCC
Steering Committee Leadership
'JSTU:FBS$MJOJDBM3FTJEFODZ
4FDPOE:FBS1IBSNBDFVUJDBM*OEVTUSZ3FTJEFODZ
$VSSFOU3FTJEFOUT
3FDFOU"MVNOJ5FTUJNPOJFT . . .
1BTU3FTJEFOUT. . .
"QQMJDBUJPO1SPDFTT . .
3&4*%&/$:4*5&4"/%"3&"40''0$64
FLORIDA AGRICULTURAL AND BRISTOL MYERS SQUIBB
MECHANICAL UNIVERSITY 3401 Princeton Pike
10650 State Road84 Lawrenceville, NJ 08648
Davie, FL 33324
2
3&4*%&/CY PROGRAM OVERVIEW
This pharmaceutical industry residency program was founded in 2009 as a partnership between
Florida A&M University and Bristol Myers Squibb. The vision of the residency is to attract and
develop a diverse group of talented pharmacists who bring clinical expertise, innovative ideas, and
dedication to improving patient outcomes.
The program provides a two-year residency in the therapeutic area of oncology. This residency
will provide the residents with a unique experience that bridges the gap between clinical practice
and the pharmaceutical industry.
,DPHODWHGWKDWFlorida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of
Public Health (FAMU CoPPS, IPH)KDVPDLQWDLQHGDIUXLWIXOSDUWQHUVKLSZLWK%ULVWRO
0\HUV6TXLEE %06 DJOREDO pharmarHVLGHQF\WUDLQLQJprogram, which significantly enchances
WKHVNLOOVRISUDFWLWLRQHUV while improving patients' health and attracting residents who help
WUDLQ3KDUP'VWXGHQWV 7KHJRDORIWKHSURJUDPLVWRSURYLGHWKHUHVLGHQWZLWKDVXEVWDQWLDO
H[SHULHQFHLQWKHSKDUPDFHXWLFDOLQGXVWU\DQGWRHPSKDVL]HWKHLPSRUWDQFHRIFOLQLFDOSUDFWLFH
WHDFKLQJ,DQGUHVHDUFK
+0)//*&L. &"3-:, II,1)% RPh,
Fellow NPhA 7KHSDUWQHUVKLSZLWK%06DOLJQVZLWKWKHYLVLRQRIWKH&ROOHJHRI3KDUPDF\DQG3KDUPDFHXWLFDO
'HDn & Professor 6FLHQFHVWRSURYLGHH[FHOOHQWSKDUPDFHXWLFDOHGXFDWLRQUHVHDUFKDQGVHUYLFHDFWLYLWLHVVWDWHZLGH
&ROOHJHRI3KDUPDF\ QDWLRQDOO\,DQGJOREDOO\LQDG\QDPLFKHDOWKFDUHHQYLURQPHQW
DQG3KDUPDFHXWLFDO6FLHQFHV,
Institue of Public Health ,WLVP\KRSHWKDWOHDUQHUVFRQVLGHUWKLVXQLTXHWUDLQLQJSURJUDPLQFOLQLFDODQGSKDUPDFHXWLFDO
)ORULGD$ 08QLYHUVLW\ LQGXVWU\."
'-03*%"".6/*7&34*5:
TheFlorida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health program offers PharmD, M.S., and
Ph.D. degrees to its students. With its main campus in Tallahassee, Florida, it is the only pharmacy program in the United States
that has a fully accredited Institute of Public Health both on-site and managed by the College of Pharmacy. The College has
additional practice centers in Jacksonville, Davie, Tampa, and Crestview, which support the infrastructure for the College’s
statewide commitment to pharmacy education and public service.
The evolution of the College has witnessed the initiation of pharmacy education with just one student in the beginning to now
being one of the largest colleges of pharmacy in the country. Currently, the College has more than 1,000 students and faculty.
FAMU CoPPS, IPH has a rich history of producing high-caliber graduates capable of providing exceptional pharmaceutical care.
Our unique program focuses on academic excellence, research superiority, and community service; this allows us to prepare
students for leading roles in the practice of pharmacy, research, and public health.
The Florida A&M College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health reinforces its primary mission
through an active role and responsibility in the delivery, outcome, and study of pharmaceutical care services it shares with other
healthcare providers. The College is committed to the advancement of pharmaceutical knowledge through teaching, research, and
service in a supportive and caring environment that enhances the attainment of educational excellence and the highest standards in
professional and ethical practice.
3
#3*450- .:&34426*##
%ULVWRO 0\HUV6TXLEELVDJOREDO%LR3KDUPDFRPSDQ\ÀUPO\IRFXVHGRQLWV
PLVVLRQWRGLVFRYHUGHYHORSDQGGHOLYHULQQRYDWLYHPHGLFLQHVWKDWKHOS
SDWLHQWVSUHYDLORYHUVHULRXVGLVHDVHV:HFRQFHQWUDWHRXUUHVHDUFK
HIIRUWVLQIRXUFRUHWKHUDSHXWLFDUHDV &DUGLRYDVFXODU,PPXQRVFLHQFH
2QFRORJ\,DQGFibrosis
$W%ULVWRO 0\HUV6TXLEERXU%LR3KDUPDVWUDWHJ\XQLTXHO\FRPELQHVWKH
UHDFKDQGUHVRXUFHVRIDPDMRUSKDUPDFHXWLFDOFRPSDQ\ZLWKWKH
HQWUHSUHQHXULDOVSLULWDQGDJLOLW\RIDVXFFHVVIXOELRWHFKQRORJ\FRPSDQ\
,QQRYDWLRQLVDWWKHKHDUWRIHYHU\WKLQJZHGR,QQRYDWLRQVSDUNVWKH
JURXQGEUHDNLQJVFLHQFHRIRXUODERUDWRULHVWKHVWDWHRIWKHDUW
SURFHVVHVLQRXUPDQXIDFWXULQJSODQWVDQGRXUSLRQHHULQJDSSURDFKWR
SURGXFWFRPPHUFLDOL]DWLRQ
:HDUHFRPPLWWHGWRWKHKLJKHVWVWDQGDUGVRIHWKLFVDQGLQWHJULW\DQG
SURPRWLQJHFRQRPLFVRFLDODQGHQYLURQPHQWDOVXVWDLQDELOLW\$W%ULVWRO
0\HUV6TXLEEZHDUHSDVVLRQDWHDERXWVFLHQFHSDVVLRQDWHDERXW
LQQRYDWLRQDQGSDVVLRQDWHDERXWPDNLQJDGLIIHUHQFHLQWKHOLYHVRI
SDWLHQWV
STEERING COMMITTEE LEADERSHIP
"%ULVWRO 0\HUV6TXLEELVDFRPSDQ\FRPPLWWHGWRSDWLHQWVDQGRIIHUV
WUHPHQGRXVRSSRUWXQLWLHVIoUSKDUPDFLVWVZLWKDQLQWHUHVWLQMRLQLQJWKH
SKDUPDFHXWLFDOLQGXVWU\%RWKRIXVHQWHUHG%ULVWRO 0\HUV6TXLEEWKURXJK
WKH 5XWJHUV8QLYHUVLW\3KDUP')HOORZVKLSSURJUDPWKXVKDYHILUVWKDQG
H[SHULHQFHRQ WKHLPSDFWWKDWSUHFHSWRUVPHQWRUVDQGWKHSKDUPDFLVW
FRPPXQLW\KDYH RQRXULQFRPLQJIHOORZVDQGUHVLGHQWV1RZDVPDQDJHUV
DQG VSRQVRUVRIWKHSURJUDPZHDUHSURXGWRIRVWHUDQHQYLURQPHQWZKHUH
PHPEHUVRIRXU 3KDUP'SURJUDPDUHSURYLGHGRSSRUWXQLWLHVWRJDLQ
H[SHULHQFHDQGQHZ VNLOOVWKDWZLOOSUHSDUHWKHPIRUIXWXUHRSSRUWXQLWLHVWR
VXFFHHGLQWKHSKDUPDFHXWLFDOLQGXVWU\
Left to right: Steering Committee Members: Carol $VOHDGHUVDW%ULVWRO 0\HUV6TXLEEZHNQRZWKHLPSRUWDQFH of investing
Davis-Shiloh, Mark Peters, Priya Darouian,
Thomas Lehman (not pictured)
LQDQGHQJDJLQJWDOHQWWRIXOILOORXUFRPSDQ\·V mission for patients. The
Executive Sponsors: Samantha Gothelf, Melissa )ORULGD$ 08QLYHUVLW\3KDUP'5HVLGHQF\LVDQLPSRUWDQW part of our
Harris; WDOHQWVWUDWHJ\DQGNH\WRFXOWLYDWLQJWKH%ULVWRO 0\HUV Squibb culture and
LWV IXWXUH"
Samantha Gothelf, PharmD and Melissa Harris, PharmD
'*345:&"3$-*/*$"-3&4*%&/$:
In the first year, residents will participate in clinical pharmacology and pharmacy practice with
emphasis in hematology, oncology, and transplant medicine at practice sites located in South Florida
and Florida A&MCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health. The
resident will actively provide pharmaceutical care to oncology patients in a variety of areas which
include: internal medicine, primary care, ambulatory care, critical care, managed care, transplant,
nutrition support, infectious disease, and geriatrics. While at the College, the residents will also
participate in workshops, meetings, and other faculty related engagements to promote professional
growth.
The resident will also be given the opportunity to participate in the pharmacy and therapeutics
committee, perform medication utilization evaluations, and provide continuing education to healthcare
practitioners. As an academic requirement, the resident will participate in teaching and preceptorship
/"5)"/& activities with FAMU student pharmacists enrolled in the college. Residents have the opporuntity to:
&3"*,)6&.&/
1)"3.% • 3URYLGeSKDUPDFHXWLFDOFDUHDQGSDWLHQWHGXFDWLRQZLWKLQLQSDWLHQWDQGRXWSDWLHQWVHWWLQJV
• 'HOLYHUOHFWXUHVWRVWXGHQWSKDUPDFLVWVSKDUPDFLVWVQXUVHVDQGPHGLFDOUHVLGHQWV
)LUVW
$633&/53&4*%&/54
AARON NORTH RICHIE ONWUCHEKWA
1)"3.% 1)"3.%
US Immunoscience WW Oncology
Medical Strategy - Publications - Early
Ozanimod Resident Transition Assets Resident
Lawrenceville1- Lawrenceville1-
QG
1"453&4*%&/54
BRYANDT DOUGLAS VICTORIA SPENCE,
1)"3.% 1)"3.%
Hematology Medical Science Thoracic & Immuno-Oncology Medical
Liaison, Bristol Myers Squibb Science Liaison, AstraZeneca
:RUOGZLGH2QFRORJ\0HGLFDO US Immuno-Oncology Medical Strategy
3XEOLFDWLRQV5HVLGHQW 2017-2019 Resident 2017-2019
KEVIN CLARKE, JESSIE HWANG,
1)"3.% 1)"3.%
Global Medical Communication Associate Director, Business
Manager, Vertex Pharmaceuticals Development , %ULVWRO 0\HUV6TXLEE
:RUOGZLGH2QFRORJ\0HGLFDO :RUOGZLGH2QFRORJ\0HGLFDO
3XEOLFDWLRQV5HVLGHQW 2016-2018 3XEOLFDWLRQV5HVLGHQW 2017-2018
MARISSA WEST, SHANADA MONESTIME,
1)"3.% 1)"3.%, BCOP
I-O Medical Scientist, US +HPDWRORJ\2QFRORJ\$VVistant3URIHVVRU
Medical Oncology, 8QLY.RI1RUWK7H[DV&ROOeJHRI3KDUPDF\
%ULVWRO 0\HUV6TXLEE :RUOGZLGH2QFRORJ\0HGLFDO&RQWHQW
:RUOGZLGH2QFRORJ\0HGLFDO ,QIRUPDWLRQ5HVLGHQW2015-2017
3XEOLFDWLRQV5HVLGHQW2015-2017
+"%&)0"/( TEMEITOPE OSIYEML,
1)"3.% 1)"3.%
Rheumatology Professional
0HGLFDO6FLHQFH'LUHFWRU
Marketing %ULVWRO 0\HUV6TXLEE
*HQHQWHFK
5 '6WUDWHJ\DQG$QDO\WLFV5HVLGHQW
0HGLFDO,QIRUPDWLRQ5HVLGHQW
*+&0."/8046
KARINA UTKINA,
1)"3.%
I-O Medical Scientist, US
1)"3.%
Medical Oncology, Medical Director, Medical Affairs
Bristol Myers Squibb Pharmacosmos Therapeutics Inc.
0HGLFDO,QIRUPDWLRQ5HVLGHQW 5 '6WUDWHJ\DQG$QDO\WLFV5HVLGHQW
%"8/#&: OLAKIITAN BABALOLA,
1)"3.%, MBA 1)"3.%
Director, Field Real World Oncology Regional Medical Scientific
EvidenceTaiho Oncology Director, Merck
5 '6WUDWHJ\DQG$QDO\WLFV5HVLGHQW 0HGLFDO,QIRUPDWLRQ5HVLGHQW
-*/"SINGLETON $)3*45*/"83*()5
1)"3.% 1)"3.%
Director Strategy & Operations Immunology/Multiple Sclerosis Senior
U.S. Oncology Medical, Novartis Regional MHGLFDO6FLHQFH/LDLVRQ
0HGLFDO,QIRUPDWLRQ5HVLGHQW Bristol Myers Squibb
0HGLFDO,QIRUPDWLRQ5HVLGHQW
7
"11-*$"5*0/130$&44
"11-*$"5*0/."5&3*"-4%6&MONDAY, NOVEMBER 2ND 2020
26"-*'*$"5*0/4
• 5HTXLUHG 'RFWRURI3KDUPDF\ 3KDUP' GHJUHHIURPDQ "11-*$"5*0/."5&3*"-4
DFFUHGLWHGLQVWLWXWLRQSULRUWRWKHVWDUWRIWKHUHVLGHQFy. • /HWWHURI,QWHQW
• Selected candidates must be licensed as a pharmacist • &XUULFXOXPYLWDH
prior to or within 90 days of starting the 1st Year Unofficial TUDQVFULSW
Clinical Residency. •7KUHHOHWWHUVRIUHFRPPHQGDWLRQ
• This program does not currently sponsor candidates for
H-1B status to work as pharmacy residents. 130$&44
• 6HOHFWedFDQGLGDWHVZLOOEHFRQWDFWHGIRUDQRQVLWHLQWHUYLHZ
• 2QHFDQGLGDWHZLOOEHVHOHFWHGIRUHDFKSRVLWLRQ
SUBMISSION:
$OOFDQGLGDWHVZLOOEHQRWLÀHGRIWKHLUVWDWXVE\WKHHQGRI
• Click here to submit application material
)HEUXDU\21
• For questions please contact FAMU@bms.com NOUS2003429-019/20
You can also read
